Table 4. Additional differentially abundant plasma metabolites (FDR < 10%).
| Target | ∆PH-∆Control | p-value | FDR |
|---|---|---|---|
| PC ae C36:3 | −0.22 | 9.90E-05 | 1.15E-03 |
| PC ae C42:2 | −0.19 | 1.82E-04 | 1.86E-03 |
| lysoPC a C20:3 | −0.26 | 1.90E-04 | 1.86E-03 |
| PC ae C40:6 | −0.20 | 1.95E-04 | 1.86E-03 |
| Tyr | −0.23 | 2.13E-04 | 1.91E-03 |
| PC ae C40:1 | −0.25 | 2.67E-04 | 2.25E-03 |
| PC ae C32:1 | −0.16 | 4.14E-04 | 3.31E-03 |
| PC aa C42:4 | −0.18 | 4.57E-04 | 3.47E-03 |
| PC ae C34:0 | −0.21 | 6.17E-04 | 4.47E-03 |
| PC ae C42:3 | −0.19 | 6.92E-04 | 4.78E-03 |
| PC aa C40:2 | −0.19 | 7.83E-04 | 5.16E-03 |
| PC aa C40:3 | −0.16 | 8.15E-04 | 5.16E-03 |
| PC ae C32:2 | −0.17 | 8.60E-04 | 5.23E-03 |
| PC ae C40:5 | −0.16 | 9.25E-04 | 5.36E-03 |
| PC aa C36:0 | −0.48 | 9.52E-04 | 5.36E-03 |
| PC aa C36:1 | −0.19 | 1.04E-03 | 5.66E-03 |
| PC ae C38:3 | −0.18 | 1.17E-03 | 6.11E-03 |
| PC ae C34:3 | −0.19 | 1.28E-03 | 6.40E-03 |
| lysoPC a C24:0 | −0.18 | 1.31E-03 | 6.40E-03 |
| Kynurenine | −0.23 | 2.00E-03 | 9.52E-03 |
| PC ae C34:2 | −0.17 | 2.39E-03 | 1.10E-02 |
| PC ae C40:4 | −0.14 | 2.60E-03 | 1.16E-02 |
| lysoPC a C20:4 | −0.21 | 2.80E-03 | 1.22E-02 |
| PC aa C38:6 | −0.18 | 3.08E-03 | 1.30E-02 |
| SM (OH) C22:1 | −0.14 | 3.20E-03 | 1.31E-02 |
| PC ae C36:1 | −0.16 | 3.31E-03 | 1.32E-02 |
| PC aa C42:2 | −0.16 | 3.48E-03 | 1.33E-02 |
| PC ae C44:3 | −0.13 | 3.50E-03 | 1.33E-02 |
| Ser | 0.16 | 3.58E-03 | 1.33E-02 |
| Trp | −0.17 | 5.07E-03 | 1.84E-02 |
| SM C24:0 | −0.13 | 5.22E-03 | 1.85E-02 |
| Gly | 0.14 | 5.48E-03 | 1.89E-02 |
| lysoPC a C18:0 | −0.17 | 6.95E-03 | 2.35E-02 |
| PC aa C42:1 | −0.13 | 7.27E-03 | 2.40E-02 |
| PC ae C42:1 | −0.13 | 7.72E-03 | 2.45E-02 |
| PC ae C30:2 | −0.13 | 7.72E-03 | 2.45E-02 |
| PC ae C40:3 | −0.12 | 8.28E-03 | 2.57E-02 |
| SM (OH) C14:1 | −0.12 | 8.60E-03 | 2.61E-02 |
| C7-DC | 0.22 | 1.07E-02 | 3.19E-02 |
| PC aa C42:6 | −0.12 | 1.35E-02 | 3.93E-02 |
| PC ae C44:4 | −0.11 | 1.38E-02 | 3.93E-02 |
| C5-OH (C3-DC-M) | −0.18 | 1.39E-02 | 3.93E-02 |
| PC ae C40:2 | −0.12 | 1.68E-02 | 4.63E-02 |
| PC aa C38:5 | −0.16 | 1.76E-02 | 4.77E-02 |
| SM (OH) C16:1 | −0.12 | 1.83E-02 | 4.89E-02 |
| PC aa C36:4 | −0.08 | 2.05E-02 | 5.36E-02 |
| PC ae C38:0 | −0.19 | 2.16E-02 | 5.56E-02 |
| PC aa C32:0 | −0.11 | 2.54E-02 | 6.44E-02 |
| Phe | −0.10 | 2.64E-02 | 6.57E-02 |
| C5-DC (C6-OH) | −0.18 | 2.78E-02 | 6.83E-02 |
| PC aa C34:3 | 0.16 | 3.15E-02 | 7.61E-02 |
| Orn | 0.13 | 3.24E-02 | 7.70E-02 |
| PC ae C34:1 | −0.11 | 3.37E-02 | 7.88E-02 |
| PC ae C42:4 | −0.10 | 3.72E-02 | 8.57E-02 |
| lysoPC a C26:0 | −0.14 | 3.81E-02 | 8.65E-02 |
| lysoPC a C16:1 | −0.17 | 3.87E-02 | 8.66E-02 |
| PC aa C32:1 | −0.22 | 4.07E-02 | 8.97E-02 |
Delta was calculated after log2 transformation of metabolite expression data (μM), computing the difference between post-treatment and baseline for each patient, and computing the average of that difference separately for PH and control groups.